

CHARGE: 502(a)—while held for sale, the labeling contained false and misleading representations that the article was adequate and effective to control the cholesterol level of the blood, and for the treatment and prevention of heart disease and atherosclerosis.

The article was alleged also to be misbranded under the provisions of the law applicable to foods, as reported in notices of judgment on foods.

DISPOSITION: 10-10-61. Default—destruction.

6884. Rexall Super Plenamins. (F.D.C. No. 44863. S. Nos. 43-373/5 R.)

QUANTITY: 137 cases, 12 8-oz. ctnd. btls. each, of *Super Plenamins Junior Liquid Vitamins*; 27 cases, 144 36-tablet btls. each, 108 cases, 36 72-tablet btls. each, 19 cases, 24 288-tablet btls. each, and 169 cases, 36 144-tablet btls. each, of *Super Plenamins Multi Vitamins with Minerals*; and 6 cases, 144 36-tablet btls. each, 7 cases, 144 72-tablet btls. each, and 9 cases, 72 144-tablet btls. each, of *Super Plenamins Junior*, at Portland, Oreg.

SHIPPED: Between 10-13-59 and 8-24-60, from St. Louis, Mo., by Rexall Drug Laboratory.

LABEL IN PART: (Btl.) "For Children 1 to 12 years * * * Rexall Super Plenamins Junior Liquid Vitamins 10 Vitamins with Red Vitamins B₁₂ plus L-lysine * * * Rexall Drug Company"; (ctn.) "Rexall Super Plenamins Junior * * * Provide generous amounts of all the vitamins children are known to need for health growth (contains L-lysine, a growth-aid cereal diets lack.) * * * Rexall Drug Company"; (btl. and ctn.) "Rexall Super Plenamins Multi Vitamins with Minerals 11 Vitamins and 12 Minerals with B₁₂, Iron plus Liver Concentrate * * * Rexall Drug Company" and "Rexall Super Plenamins Junior 11 Vitamins with B₁₂ plus Iron and Liver Rexall Drug Company."

ACCOMPANYING LABELING: Leaflets entitled "Who Wouldn't Pay A Nickel A Day?" "Free 18 Day Supply Super Plenamins," and "Know Who Makes the Vitamins you BUY?" used in promoting sales of "Super Plenamins Multi Vitamins with Minerals."

LIBELED: 8-25-60, Dist. Oreg.; amended libel 1-26-61.

CHARGE: 502(a)—when shipped and while held for sale, the labeling contained false and misleading representations that the articles were adequate and effective for the treatment and prevention of (*Super Plenamins Junior Liquid Vitamins*) nervous irritability, constipation, indigestion, and loss of energy in children; that the presence of these conditions indicates that there is an increased need for the vitamins, iodine, and L-lysine in the article; and that the vitamins and L-lysine in the article would promote healthy growth in children; (*Super Plenamins Multi Vitamins with Minerals*) lack of appetite, loss of energy, nervous irritability, insomnia, constipation, indigestion, rundown condition, listlessness, and lack of "get up and go"; that the article would stimulate red blood cell formation because it contained the combination of red vitamin B₁₂, folic acid, vitamin C, liver concentrate, and iron; and that use of the article would result in feeling one's best every day, enjoyment of life to the fullest, and getting the most out of life; and (*Super Plenamins Junior tablets*) lack of appetite, loss of energy, listlessness, nervous irritability, insomnia, constipation, indigestion, and rundown condition in growing children; that the presence of these conditions indicates that there is an increased need for the vitamins in the article; and that the article would stimulate red

blood cell formation because it contained the combination of red vitamin B₁₂, folic acid, vitamin C, liver concentrate and iron.

The articles were alleged also to be misbranded under the provisions of the law applicable to foods, as reported in notices of judgment on foods.

DISPOSITION: 6-8-61. The Rexall Drug & Chemical Co., claimant, having consented to the entry of a decree which declared the articles to be misbranded under 403(j) as alleged in the libel, and the court having found the articles to be misbranded under 403(j) without an adjudication of the other charges of misbranding, judgment of condemnation was entered and the articles were released under bond for relabeling.

6885. Rexall Bislumina Acid Guard tablets. (F.D.C. No. 45523. S. Nos. 26-379/80 R, 27-161 R, 27-169 R.)

QUANTITY: 124 cases, each containing a number of ctns., containing 1 50-tablet btl. and 1 6-tablet vial each, at Los Angeles and Vernon, Calif.

SHIPPED: Between 10-14-60 and 3-20-61, from St. Louis, Mo., by Rexall Drug Co.

LABEL IN PART: (Cases, ctns., btls., and insert label in vials) "Rexall Bislumina Acid Guard for relief from gastric hyperacidity contains bismuth aluminate * * * Rexall Drug Company * * * Los Angeles-St. Louis-Toronto * * * Each tablet contains: Magnesium Carbonate 400 mg; Calcium Carbonate (Chalk) 200 mg; Bismuth Aluminate 150 mg; Cortext Frangula (Buckthorn Bark) 25 mg; Calamus Root 25 mg; Carboxymethylcellulose Sodium, Peppermint Oil."

ACCOMPANYING LABELING: Leaflets entitled "Rexall Bislumina Acid Guard An amazing new tablet formulation brings prompt relief to both groups of your patients. For Physician's Information Only."

LIBELED: 3-23-61, S. Dist. Calif.

CHARGE: 502(a)—when shipped, the labeling of the article, namely, the leaflets accompanying the article, contained false and misleading representations that the article was an adequate and effective treatment for peptic ulcers.

DISPOSITION: 5-2-61. Consent—claimed by Rexall Drug & Chemical Co. and leaflets destroyed.

6886. Cobalamed 1000 injection. (F.D.C. No. 46066. S. No. 2-908 R.)

QUANTITY: 300 10-cc.vials, individually ctnd., at Decatur, Ga.

SHIPPED: 6-26-61, from Chicago, Ill., by Medical Chemicals Corp.

LABEL IN PART: (Vial) "Multiple Dose Vial Cobalamed 1000 * * * Injection Cyanocobalamin U.S.P. XVI * * * 106416 Manufactured for Medics Pharmaceutical * * * Atlanta (Decatur), Ga."

ACCOMPANYING LABELING: Insert leaflets entitled "Vitamin B₁₂ Description."

LIBELED: 7-5-61, N. Dist. Ga.

CHARGE: 502(a)—when shipped, the labeling of the article contained false and misleading representations that the article was adequate and effective as a treatment for trigeminal neuralgia; toxic, diabetic, alcoholic, and nutritional neuritic disorders; bursitis; acute and chronic liver disease; viral hepatitis; dermatoses such as seborrheic dermatitis, psoriasis, lupus erythematosus, and topical dermatitis.

DISPOSITION: 11-1-61. Consent—claimed by Medical Chemicals Corp., and relabeled.